Group 1 - In January 2026, a total of 117 companies will have their restricted shares unlocked, amounting to approximately 10.202 billion shares and a total market value of 289.587 billion yuan, which is a decrease of about 14.13% month-on-month and an increase of approximately 12.57% year-on-year [1][2][4] - The company with the largest unlock scale is Baili Tianheng, with a market value exceeding 90 billion yuan [1][4] - The top three industries by unlock market value are pharmaceuticals and biotechnology, electrical equipment, and automotive [1][9] Group 2 - In January, 12 companies will have their anniversary unlocks, totaling approximately 1.028 billion shares and a market value of 54.824 billion yuan, including companies like Haibo Sichuang, Xingtou Measurement and Control, and Saifen Technology [1][11] - The second largest unlock scale is for Haibo Sichuang, with 9.464 million shares and a market value of approximately 23.937 billion yuan, accounting for about 52.55% of its total share capital [4][8] - Guolian Minsheng ranks third in unlock market value, with 1.771 billion shares, representing 31.17% of its total share capital and a market value of approximately 18.132 billion yuan [8]

Group 1 - In January 2026, a total of 117 companies will have their restricted shares unlocked, amounting to approximately 10.202 billion shares and a total market value of 289.587 billion yuan, which is a decrease of about 14.13% month-on-month but an increase of about 12.57% year-on-year [1][3][7] - The company with the largest unlock scale is Baili Tianheng, with a market value exceeding 90 billion yuan, accounting for 72.2% of its total share capital [3][4] - The top three industries by unlock market value are pharmaceuticals and biotechnology, electrical equipment, and automotive [1][8] Group 2 - In January, 12 companies will have their anniversary unlocks, totaling approximately 1.028 billion shares and a market value of 54.824 billion yuan, including companies like Haibo Sichuang and Xingtou Measurement Control [1][10] - Haibo Sichuang will have 9.464 million shares unlocked, with a market value of approximately 23.937 billion yuan, accounting for 52.55% of its total share capital [6][11] - Guolian Minsheng will have 1.771 billion shares unlocked, representing 31.17% of its total share capital, with a market value of about 18.132 billion yuan [7]

Group 1 - In January 2026, a total of 117 companies will have their restricted shares unlocked, amounting to approximately 10.202 billion shares and a total market value of 289.587 billion yuan, which is a decrease of about 14.13% month-on-month and an increase of about 12.57% year-on-year [1][2] - The company with the largest unlock scale is Baili Tianheng, with a market value exceeding 900 billion yuan [1][4] - The top three industries by unlock market value are pharmaceuticals and biotechnology, electrical equipment, and automotive [1][8] Group 2 - In January, 12 companies will have their anniversary unlocks, totaling approximately 1.028 billion shares and a market value of 54.824 billion yuan, including companies like Haibo Sichuang, Xingtou Measurement and Control, and Saifen Technology [1][10] - The second largest unlock scale is for Haibo Sichuang, with 9.464 million shares and a market value of approximately 239.37 billion yuan, accounting for 52.55% of its total share capital [7][12] - The third largest unlock is for Guolian Minsheng, with 1.771 billion shares, representing 31.17% of its total share capital and a market value of approximately 181.32 billion yuan [7][12]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The pharmaceutical and biotechnology sector experienced a weekly return of -2.06%, ranking 28th among 31 primary sub-industry indices, with the medical services sub-sector performing the best at -1.40% [3][9] - Emerging industries such as brain-computer interfaces, robotics, and AI applications are highlighted as key areas of focus for investment in 2026, alongside state-owned enterprise reforms as part of the "14th Five-Year Plan" [3][9] - Long-term investment themes include innovation and international expansion, with recommendations to focus on high-end medical devices and innovative drug supply chains [3][9] Summary by Sections 1. Industry Weekly Viewpoints - The medical services sub-sector had the highest weekly return, while the pharmaceutical commercial sub-sector ranked sixth with a return of -2.68% [9] - The report emphasizes the importance of new industries and state-owned enterprise reforms for investment opportunities in 2026 [3][9] 2. Pharmaceutical Sector Performance and Valuation - The pharmaceutical and biotechnology industry index had a recent one-month return of -2.97%, ranking 29th among primary sub-indices [11] - The current PE (TTM) for the pharmaceutical and biotechnology industry is 28.59 times, slightly below the five-year historical average of 28.62 times [15][18] 3. Market Tracking - The medical services sub-sector showed the smallest weekly decline, while it also had the highest monthly return of 1.91% [28] - The report provides detailed performance metrics for various sub-sectors, indicating a mixed performance across the board [25][28] 4. Industry and Company Dynamics - Recent policy developments include the implementation of a unified basic medical insurance management procedure in Guangdong Province, effective February 1, 2026 [35] - Significant news includes the approval of new drugs and clinical trials by various companies, indicating ongoing innovation in the sector [36][37]

Group 1 - The report emphasizes the potential for a second wave of growth in small-cap stocks, particularly those representing new productive forces in the North Exchange, as the market transitions into the spring season [1][11][19] - The North Exchange 50 Index closed at 1,440.43 points, with a P/E ratio of 60.29X, while the North Exchange specialized and innovative index stood at 2,424.18 points with a P/E ratio of 75.82X [2][34] - The report highlights the performance of various sectors, with the P/E ratios for high-end equipment, information technology, new chemical materials, consumer services, and biomedicine being 39.63X, 87.10X, 44.14X, 48.21X, and 36.12X respectively [2][45][50] Group 2 - In 2025, the North Exchange saw 26 new listings, with an average first-day increase of 368.13%, and the standout performer, Hengtong Light, achieved a first-day increase of 878.16% [3][20] - The report suggests that the North Exchange is currently in a favorable position for investment, particularly in technology-driven companies that are likely to benefit from ongoing policy support and market trends [1][51] - The report recommends a focus on specific stocks within the North Exchange, including those in the information technology chain such as Wanyuantong, and in the chemical new materials chain such as Better Energy and Andatech [2][51]

"含A量"飙升：A+H模式成龙头出海新范式 2025年，维多利亚港畔的上市锣声格外密集——全年117家企业敲钟登场，平均每两个交易日便有一声清脆回响。 伴随这密集的节奏，香港交易所以预计超2800亿港元的IPO募资总额，时隔多年重夺全球新股融资榜首。恰逢港 交所成立二十五周年，这场"王者归来"不仅是一次规模上的胜利，更标志着港股市场核心叙事的根本性转变：从 昔日的"估值洼地"，正加速跃升为汇聚中国优质资产与新经济动能的"产业高地"。 驱动这一跃迁的，是两大结构性力量："含A量"的显著提升与"向新力"的强劲迸发。 2025年港股IPO市场的最大亮点之一，是A股优质企业集体"南下"。据德勤预测，全年港股IPO募资额达2863亿港 元（约360亿美元），其中近半数来自A股公司——19家A股上市公司成功登陆港股，合计募资1399.93亿港元，占 比高达48.9%。 尤为引人注目的是，在募资前十大的IPO中，6家为"A+H"双上市企业：动力电池巨头宁德时代、医药龙头恒瑞医 药、调味品白马海天味业，以及三一重工、赛力斯、三花智控等行业领军者。仅这六家便贡献了1033亿港元，占 全年总额的36%以上。此外，募资第二的紫金黄 ...

Core Viewpoint - The A-share market in 2025 is expected to show a structurally strong trend, with public funds significantly increasing their research efforts on listed companies, totaling 2,434 companies and over 75,000 research instances [1][2]. Group 1: Research Overview - In 2025, 165 public fund institutions conducted research on A-share listed companies, covering all 31 primary industries and involving 2,434 individual stocks, with a total of 76,285 research instances [2]. - A total of 169 stocks received high-frequency attention from public funds, with each stock being researched at least 100 times; 30 stocks exceeded 200 research instances, highlighting them as core market targets [2]. - The most researched stock was Huichuan Technology in the machinery sector, with 497 instances, followed by Zhongkong Technology and Jereh with 314 and 286 instances, respectively [2]. Group 2: Sector Focus - The electronics sector emerged as the most researched industry in 2025, with 14,009 research instances covering 286 stocks, indicating its core position in the technology growth area [4]. - The pharmaceutical and machinery sectors followed, with 9,927 and 9,469 research instances, respectively, reflecting ongoing institutional interest in high-quality companies supported by rigid demand in healthcare [4]. - Other sectors such as power equipment, computers, and automobiles also attracted significant attention, each with over 4,000 research instances, aligning with the current economic transformation and upgrade direction [5]. Group 3: Future Market Outlook - For 2026, the recovery of profits and the technology sector are identified as the two core themes for public funds, with the AI industry expected to remain a key growth driver [6][7]. - The market is anticipated to become more rational, with investors focusing on the commercial viability of technology and the authenticity of performance delivery [7]. - The recovery in profitability is expected to be driven by spontaneous clearing in the industry, with policy playing a supportive role, leading to differentiated investment opportunities across sectors [7].

Group 1 - The overall A-share market in 2025 shows a structurally strengthening trend, with public funds significantly increasing their research efforts on listed companies, totaling 2,434 companies researched and over 75,000 research instances [1][2] - The AI industry chain is expected to continue being a core theme in the technology growth sector, with leading companies that achieve substantial breakthroughs in key technologies and hold a leading position in application scenarios being the main targets for long-term growth expectations [1][6] Group 2 - In 2025, 165 public institutions participated in A-share company research, covering all 31 first-level industries and involving 2,434 individual stocks, reflecting a strong emphasis on fundamental research by public institutions [2] - The mechanical equipment sector saw the highest research frequency, with the company "汇川技术" receiving 497 research instances, making it the most favored stock by public funds [2] - The electronics sector also performed well, with four companies in the top ten for research frequency, including "立讯精密" with 422 instances, indicating a strong interest in this sector [3][4] Group 3 - The electronics industry emerged as the most researched sector in 2025, with a total of 14,009 research instances covering 286 stocks, highlighting its core position in the capital market [4] - The pharmaceutical and mechanical equipment sectors followed closely, with 9,927 and 9,469 research instances respectively, indicating ongoing interest in high-quality companies within these industries [4][5] Group 4 - Other sectors such as power equipment, computers, and automobiles also attracted significant attention from public institutions, each with over 4,000 research instances, contributing to a matrix of high-interest sectors [5] - The focus of these high-interest sectors aligns with the current economic transformation and upgrading direction, emphasizing technology innovation and high-end manufacturing [5] Group 5 - Looking ahead to 2026, the recovery of profits and the technology theme are identified as two core keywords for the market, with expectations for the AI industry chain to remain a central focus [6][7] - The recovery of A-share company profits is anticipated to gradually bottom out, driven by spontaneous clearing in the industry, with policy playing a supportive role [7]

Core Viewpoint - The A-share market is expected to continue its upward trend in 2026, with a focus on technology growth, resource sectors, and high-dividend stocks as key investment themes [2][10][18]. Group 1: Market Outlook for 2026 - The overall A-share market is anticipated to remain strong, with a shift from a policy-driven to a fundamentals-driven growth narrative [12][20]. - The global monetary environment is expected to be supportive, with the U.S. in a rate-cutting cycle, providing liquidity for the market [19]. - Structural opportunities and upward pressures will coexist, with challenges increasing in complexity [8][19]. Group 2: Investment Strategies - A balanced allocation between value and growth stocks, as well as large-cap and small-cap stocks, is recommended for 2026 [14][25]. - The focus on technology growth remains strong, particularly in AI, semiconductors, and new energy sectors, benefiting from global capital expenditure expansion and domestic policy support [20][30]. - High-dividend stocks are seen as stabilizers in the investment portfolio, especially in a low-interest-rate environment [30][21]. Group 3: Key Sectors to Watch - AI is expected to remain a primary growth driver, with specific attention to areas such as optical communication, storage chips, and domestic computing power breakthroughs [27][30]. - The innovation drug sector is highlighted as a long-term focus, supported by domestic healthcare policies [28]. - Resource sectors, including industrial metals and precious metals, are projected to benefit from supply chain restructuring and AI demand [30][21]. Group 4: Hong Kong Market Outlook - The Hong Kong market is expected to experience a new trend driven by valuation recovery, profit growth, and a return to AI as a main theme [32][34]. - Key investment opportunities in Hong Kong are anticipated in technology, resources, and healthcare sectors, with a focus on high-dividend stocks [36][37]. - The influx of capital from mainland China is expected to continue supporting the Hong Kong market [33][34].

Core Insights - The Hong Kong capital market is set for a full recovery in 2025, with total IPO fundraising exceeding HKD 285.8 billion, reclaiming its position as the leading global exchange, indicating a significant rebound in Hong Kong's attractiveness as an international financial center [1][2] Group 1: IPO Market Performance - In 2025, a total of 119 companies went public in Hong Kong, representing a 63% increase from the previous year, with total fundraising amounting to HKD 285.8 billion, a staggering 2.25 times increase year-on-year [2] - The top ten IPOs of the year included eight companies that raised over HKD 10 billion, with CATL leading at HKD 41.0 billion and Zijin Mining at HKD 42.8 billion, making them the largest and second-largest IPOs globally [2] - A-share companies played a crucial role in the Hong Kong IPO market, with 19 A-share firms raising approximately HKD 140 billion, nearly half of the total IPO fundraising in Hong Kong [2] Group 2: Market Drivers - The surge in IPO activity is driven by the concentrated listing of Chinese tech companies, a wave of A-share companies listing in Hong Kong, and a significant improvement in market liquidity [1][2] - The introduction of the "Specialized Technology Company Fast Track" service and the ongoing appeal of Listing Rules Chapter 18A and Chapter 18C have opened up listing avenues for unprofitable biotech and specialized tech companies [1][3] Group 3: Institutional Reforms - Continuous institutional innovations have been pivotal for the strong performance of the Hong Kong stock market, including the introduction of Chapter 18A in April 2018, allowing unprofitable biotech companies to apply for listings [3] - By the end of 2025, 88 biotech and specialized tech companies had listed under these new rules, with 16 companies listing in 2025 alone [3] - The average daily trading volume in the first 11 months of 2025 was HKD 255.8 billion, a year-on-year increase of approximately 95%, enhancing the attractiveness of Hong Kong for international capital [3] Group 4: Future Outlook - Deloitte forecasts that with over 300 listing applications, the Hong Kong IPO market could see fundraising of at least HKD 300 billion in 2026, with around 160 new stocks expected to be issued [5] - Factors such as potential interest rate cuts by the Federal Reserve, increased support for mainland Chinese companies, and ongoing capital market reforms in Hong Kong are expected to attract more large-scale IPOs [5]